FDA Determines Regulatory Review Period for ULTRAVIST Patent Extension

Summary

The Food and Drug Administration has officially confirmed the regulatory review period for ULTRAVIST, a human drug product, in accordance with federal regulations, following a patent extension application submitted to the US Patent and Trademark Office.